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with bone metastases
D Generali1,2, A Dovio3, M Tampellini4, M Tucci4, S Tedoldi1, M Torta4, S Bonardi1, G Allevi1, S Aguggini1,
M Milani1, AL Harris2, A Bottini1, L Dogliotti4, A Angeli3 and A Berruti*,4
1Breast Unit, Azienda Ospedaliera Istituti Ospitalieri, Cremona, Italy; 2Weatherall Molecular Oncology Laboratories, Institute of Molecular Medicine, John
Radcliffe Hospital, University of Oxford, Oxford, UK; 3Medicina Interna e, Dipartimento di Scienze Cliniche e Biologiche, Universita` degli Studi di Torino –
Azienda Ospedaliera San Luigi di Orbassano, Orbassano, Italy; 4Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Universita` degli Studi di
Torino – Azienda Ospedaliera San Luigi di Orbassano, Orbassano, Italy
Persistent circadian rhythm of bone turnover in bone metastatic breast cancer suggests greater skeletal retention of bisphosphonates if
administered in the night. We assessed differential effects of night vs morning administration of zoledronic acid (ZA) on bone turnover.
Forty-four breast cancer patients with bone metastases were randomised to receive intravenous ZA (4 mg) at 1100 or 2300 hours
every 28 days for four times. Urinary concentration N-telopeptide of type-I collagen (NTX) and deoxypyridinolines, and serum
C-telopeptide of type-I collagen (CTX), bone alkaline phosphatase (ALP), osteocalcin and Parathyroid hormone (PTH) was measured in
the morning at baseline and after 4, 7, 14, 28, 56 and 84 days. Urinary ZA concentration was also measured. Zoledronic acid caused
significant decreases of NTX and CTX (Po0.001), without any difference in percent changes between night and morning arms. Bone
ALP and osteocalcin were also significantly affected by ZA (P¼ 0.001), without any difference between arms. Parathyroid hormone
significantly increased in both the arms; PTH increase was lower in the night arm (P¼ 0.001). From the second administration onwards,
urinary ZA level was significantly higher in the night arm (Po0.01). Administration of ZA at two opposite phases of the circadian cycle
causes similar changes of bone-turnover marker levels, but has differential effects on the level of serum PTH.
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Bone metastases are frequent in patients with advanced breast
cancer. A complex crosstalk between cancer cells and cells of
the bone microenvironment leads to disruption of the normal
coupling between formation and resorption, eventually resulting in
osteolytic, osteoblastic or mixed appearances. In the
vast majority of cases, increased osteoclast activity predisposes
patients to undergo adverse skeletal events such as fractures,
hypercalcaemia and spinal cord compression (Kakonen and
Mundy, 2003).
Bone-turnover markers provide valuable indirect information
regarding the changes occurring in the basic multicellular units as
a consequence of cancer colonisation and progression, and the
effects of therapy. Breakdown products of type-I collagen, such as
pyridinoline, deoxypyridinoline (DPD), N- and C-terminal telo-
peptides (NTX and CTX), are established markers of bone
resorption (Pagani et al, 2005; Seibel, 2005). They are released
into the circulation and are ultimately excreted in the urine. They
are often elevated in patients with bone metastases irrespective of
the radiological appearance of lesions; remarkably, they correlate
with extent of metastases, bone pain (Berruti et al, 1999) and
prognosis, including onset of adverse skeletal events (Brown et al,
2003, 2005; Coleman et al, 2005; Mundy, 2005). Bone resorption
has a circadian rhythm, with levels of all relevant urinary and
serum markers peaking in the early morning hours (Bjarnason
et al, 2002). We have recently demonstrated that this rhythmicity is
roughly maintained in patients with bone metastatic breast cancer
(Generali et al, 2007).
Bisphosphonates are effective in preventing skeletal complica-
tions in patients with cancer bone disease (Pavlakis et al, 2005).
Zoledronic acid (ZA), the most potent bisphosphonate available
nowadays, is widely used for this purpose (Rosen, 2004; Rosen
et al, 2004). Pertinently, the clear-cut fall of urinary NTX level after
ZA administration has been associated with reduction of adverse
skeletal events (Coleman et al, 2005). Since bisphosphonates bind
preferentially to the exposed hydroxyapatite at the resorption sites
(Lin, 1996), a higher percentage of the administered dose may be
taken up by the bone when the resorptive activity is higher, that is,
during night. In a recent investigation, Cremers et al. (2005) have
focused on the significant relationship between skeletal retention
of pamidronate and the antiresorptive effect of the drug. To
address whether nocturnal administration of ZA could lead to
differential effects with respect to conventional morning
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administration, in this study we have measured the level of
bone-turnover markers, serum calcium and parathyroid hormone
(PTH) in bone metastatic breast cancer patients at first
relapse randomised to receive the same regimen of ZA at 1100 or
at 2300 hours, that is, at two opposite phases of the circadian cycle.
MATERIALS AND METHODS
Study population
Forty-four consecutive patients (median age 62, range 32– 77
years) with bone metastatic breast cancer, consecutively recruited
at a single institution (Breast Unit, Cremona, Italy), were enrolled
into the study between January and December 2002. Patients met
the following inclusion criteria: histologically diagnosed breast
adenocarcinoma at first disease relapse; at least one apparent
metastatic site in bone (confirmed by conventional radiography,
computed tomography and/or magnetic resonance imaging) and
performance status between 0 and 2. Exclusion criteria were as
follows: chemotherapy or endocrine therapy for advanced disease
started before study entry (previous chemotherapy or endocrine
therapy, administered in an adjuvant setting, should have been
interrupted for at least one year); previous radiation therapy on
bone lesions; previous bisphosphonate treatment; concomitant
diseases known to affect bone; liver metastases; biochemical
evidence of renal or hepatic dysfunction. All patients were post-
menopausal, the menopause having been physiological in 31 and
iatrogenic in 13 of them.
The study was performed in accordance with current guidelines
on good clinical practice in clinical research and the Declaration of
Helsinki and subsequent integrations. All subjects provided
written, informed consent, and the study was approved by the
local ethical committee.
Protocol
Patients were randomised to receive ZA (4 mg diluted in 100 ml
saline, intravenously, in about 15 min) either in the morning
(approximately at 1100 hours) or in the night (approximately at
2300 hours), every 4 weeks for 4 months.
Serum levels of calcium, PTH, bone alkaline phosphatase (ALP),
osteocalcin, CTX, and urinary NTX and DPD, were measured,
respectively, in a blood sample drawn in the morning at about 0800
hours and in a second-void urine sample, at baseline (before
starting ZA), and thereafter at days 4, 7, 14, 28, 56 and 84. All
patients also had serum 25-hydroxyvitamin D level assessed at
baseline. Zoledronic acid excretion was determined in the second-
void urine samples collected at days 4, 7, 14, 28, 56 and 84. From
the second ZA administration onwards, all patients received a
combination regimen of intravenous vinorelbine (30 mg m2 on
days 1 and 8, every 21) plus oral capecitabine (2000 mg m2 on
days 1 to 14 every 21). During the study period no patient received
daily calcium and vitamin D supplementation.
At baseline, disease extent in bone was scored by arbitrarily
dividing the skeleton into the following regions: skull, cervical,
dorsal, lumbar spine-sacrum, right leg, left leg, right arm, left arm,
right ribs, left ribs, sternum, right scapula and clavicula, left
scapula and clavicula, right pelvis and left pelvis. The sum of data
from the involved areas was considered; in order to limit the
distribution of this variable, patients with more than 10 segments
were scored as 10.
Bone pain was evaluated at baseline and before each ZA
administration (i.e., after 28, 56 and 84 days) using a validated pain
questionnaire, as previously reported (Berruti et al, 2000). The
questionnaire items included performance status, analgesic con-
sumption and mobility, with a resulting pain score of 0 –19.
Biochemistry
A sampling cannula was inserted into a vein in the antecubital
fossa. At each time point the initial 2.5 ml were discarded and a
5-ml blood sample was obtained. Routine biochemical analyses
were performed with fresh samples; other aliquots were stored at
201C before being analysed (within 6 months).
Serum calcium, creatinine, albumin and total ALP, and urinary
calcium and creatinine levels were measured by standard
automated analytical procedures (Modular P/P; Roche). Serum
calcium levels were always corrected for serum albumin. Serum
PTH (intact molecule) level was measured by an immunoradio-
metric assay (IRMA; Scantibodies Laboratory, Santee, CA, USA).
Bone ALP level was measured by precipitation with wheat germ
lectin (Iso-ALP; Roche Diagnostics GmdH, Mannheim, Germany).
Osteocalcin concentration was measured by radioimmunoassay
(RIA) using a monoclonal antibody that binds intact osteocalcin
and fragments 1 –43, 20–49 and 20–44 (Osteocalcina Myria;
Technogenetics, Milan, Italy). 25-Hydroxyvitamin D was measured
by RIA (Immunodiagnostic Systems, Boldon, UK). Deoxypyridino-
line level was measured by high-performance liquid chromato-
graphy (Bio-Rad, Milan, Italy), while CTX and NTX levels were
measured by ELISAs (Nordic Bioscience Diagnostic, Herlev,
Denmark; and Osteomark, Ostex International, Seattle, WA,
USA, respectively). Zoledronic acid level in urine was measured
at a Novartis Pharma laboratory (Rueil Malmaison, France),
according to a previously described highly sensitive RIA (Legay
et al, 2002). Urinary marker levels were calculated relative to levels
of urinary creatinine.
Measuring ranges, minimum detectable concentrations, intra-
and inter-assay coefficients of variation were as follows: osteo-
calcin: 2.2–64.3 ng ml1, 0.3 ng ml1, 3.5 and 5.6%; bone ALP:
5–2000 U l1, 5 U l1, 0.5 and 2.2%; CTX: 0.156– 2.562 ng ml1,
0.01 ng ml1, 2.5 and 9%; NTX: 30–3000 nM, 20 nM, 4.4 and 6.9%;
DPD: 7–300 nM, 6 nM, 11 and 14%; PTH: 15–2000 pg ml1,
1.8 pg ml1, 3.2 and 5.8%; ZA: 1 –1000 ng ml1, 5 ng ml1, 16– 21
and 6.7– 8%. All assays were performed in duplicate. Samples from
a single subject were assayed within a single analytical session.
Statistical analysis
Comparisons of qualitative and continuous variables were by
w2 and Mann–Whitney U-tests, respectively. With regard to bone-
turnover markers, due to inter-individual differences in the
baseline levels, changes were assessed at each time point as both
absolute and percent values. With regard to PTH, it is held that
levels in the peripheral blood undergo rapid oscillations due to
ultradian rhythmicity, characterised by numerous secretory bursts
per hour. Therefore, percent changes could be quite different as a
function of a single baseline measurement occurring at the peak or
the bottom of a burst lasting only few minutes. We decided to use
absolute changes for this variable and to analyse also the area
under the curve (AUC) calculated by trapezoidal method (Allison
et al, 1995).
The time profiles were analysed by a multivariate analysis of
variance for repeated measurements according to a mixed random
effect model, which uses the covariance structure also for
estimating the model parameters (SAS PROC MIXED with
REPEATED statement and no RANDOM statement). Covariance
matrix components were separately estimated for the two
treatment arms. All P-values reported were two-sided; a 0.05 limit
was chosen for statistical significance. Only subjects with all values
were included in the model fitting. Time distances were considered
as equally spaced in the model.
Since bone resorption markers are significantly correlated with
disease extent in bone (Berruti et al, 1999), relevant data were also
analysed after adjusting for the number of bone segments
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involved. All statistical analyses were performed using SAS
software version 8.2.
RESULTS
Twenty-two patients were randomised to each treatment arm.
Patients’ characteristics are outlined in Table 1.
Zoledronic acid administration was well tolerated in both
treatment arms. Twenty patients (45.4%), 10 for each treatment
arm, experienced acute-phase reactions lasting no more than a few
days after ZA administration. Mean serum creatinine level did not
vary at any time point in either treatment arms. Zoledronic acid
administration led to a decrease in bone pain without any
difference between arms.
Effect of morning vs night ZA administration on the
markers of bone turnover
As shown in Table 2, no difference in the levels of bone resorption
and formation markers was observed between the treatment arms
at baseline. When both arms were considered together, ZA
administration led to significant decreases of urinary NTX
(Po0.001) and serum CTX (Po0.0001) levels, but not of urinary
DPD. The ANOVA performed on the levels of bone resorption
markers obtained at each time point yielded the following results
(Figure 1). Differences in mean absolute levels between the
treatment arms were significant for serum CTX (P¼ 0.05) and
urinary NTX (P¼ 0.05), but failed to attain the statistical
Table 1 Clinical characteristics of patients
Morning arm Night arm
Number of patients 22 22
Age (years) 62 (33–77) 61 (39–74)
Bone disease extent 3 (1–10) 4 (1–10)
Pain score 2 (0–4) 1.5 (0–4)
Performance status
0 16 (72.7%) 18 (81.8%)
1 3 (13.6%) 1 (4.5%)
2 3 (13.6%) 3 (13.6%)
Metastatic disease sites
Bone only 13 (59.1%) 14 (63.6%)
Bone plus lung 5 (22.7%) 6 (27.3%)
Bone plus soft tissues 4 (18.2%) 2 (9.1%)
Previous adjuvant treatments
Chemotherapy only 5 (22.7%) 6 (27.3%)
Chemotherapy+endocrine therapy 17 (77.3%) 16 (72.7%)
Data are means (95% confidence intervals) or numbers of patients (%). No statistical
difference was found between morning and night arms by w2 or Mann–Whitney
U-test.
Table 2 Bone turnover marker, serum calcium, 25-hydroxyvitamin D
and PTH level at baseline in the two treatment arms
Morning arm Night arm
Serum CTX (ng ml1) 0.77 (0.56–0.97) 0.73 (0.54–0.91)
Urinary NTX/creatinine ratio 164.4 (102.2–226.6) 138.7 (85.6–191.8)
Urinary DPD/creatinine ratio 12.8 (10.1–15.6) 11.0 (8.9–13.1)
Serum bone ALP (U l1) 34.6 (22.7–46.5) 26.3 (21.8–30.8)
Serum osteocalcin (ng ml1) 11.9 (7.5–16.3) 9.9 (7.8–11.9)
Serum calcium (mg per 100 ml) 10.1 (9.5–10.7) 9.7 (9.4–10.1)
Serum PTH (pg ml1) 43.1 (25.6–60.7) 50.7 (9.5–91.7)
Serum 25-hydroxyvitamin D (nM) 71.1 (54.9–87.3) 72.4 (56.7–88.0)
ALP¼ alkaline phosphatase; CTX¼C-telopeptide of type-I collagen; DPD¼ deoxy-
pyridinoline; NTX¼N-telopeptide of type-I collagen; PTH¼ parathyroid hormone.
Data are means (95% confidence interval).
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Figure 1 Serum CTX levels (A) and urinary NTX/creatinine (B) and
DPD/creatinine (C) ratios after ZA administration. Data are presented as
mean±s.e.; *Po0.05 vs baseline.
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significance when data were expressed as percent variations. The
profiles of mean serum levels of CTX and urinary excretion of DPD
of the two treatment arms showed progressively divergent trends
over time (tests for interaction P¼ 0.0001 and P¼ 0.0001,
respectively), whereas the profiles of urinary NTX did not
(Figure 1). Statistical analysis yielded the same results after
adjusting for disease extent in bone.
As far as bone formation markers were concerned, when both
arms were considered together, both bone ALP and osteocalcin
significantly (P¼ 0.001 for both variables) changed after ZA
administration. Osteocalcin showed a substantial decrease
(Figure 2A), whereas bone ALP showed an initial decrease followed
by transient recovery to baseline and subsequent sustained
decrease (Figure 2B). The time profiles of both markers were
analogous in both treatment arms.
Effect of morning vs night ZA administration on serum
calcium and PTH level
At baseline, patients randomised in the two treatments arms did
not differ in terms of serum calcium, PTH and 25-hydroxyvitamin
D concentrations (Table 2). When the two arms were considered
together, corrected serum calcium decreased and serum PTH
increased after ZA administration (Po0.001). When looking at
differences between the two profiles obtained by giving ZA at the
opposite phases of the 24-h cycle, serum calcium levels were
similar in both the arms in the early period, whereas differing at
days 28 (Po0.05) and 56 (P¼ 0.05), and again overlapping at day
84 (Figure 3A); however, absolute decremental AUCs were similar
in the two arms (P¼ 0.19). The time profiles of mean PTH values
showed a similar trend in both arms, yet the nocturnal regimen led
to a significant lower PTH increase as assessed both by ANOVA
(P¼ 0.001; Figure 3B) and absolute incremental AUC (P¼ 0.08).
No significant correlation was found between calcium and PTH
AUCs.
Effect of morning vs night ZA administration on
urinary ZA
Whereas similar patterns were noticed in both arms during the
first month, from the second administration onwards mean drug
levels before subsequent infusion were significantly higher in
patients randomised to receive ZA in the night with respect to
those receiving the drug in the morning (Po0.01).
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DISCUSSION
Current knowledge from experimental studies supports the notion
that there is a vicious circle at the bone metastatic site where
cancer cells stimulate osteoclast-mediated bone resorption,
whereas bone-derived factors released from the resorbed bone
promote metastasis growth (Kakonen and Mundy, 2003). A clinical
consequence of this notion is the well-recognised use of bispho-
sphonates as an important feature of the therapy of patients with
bone metastases. A direct association between the extent of skeletal
retention of intravenously administered pamidronate and suppres-
sion of bone resorption rate has been demonstrated recently in a
series of breast cancer patients with bone metastases (Cremers
et al, 2005). Baseline bone turnover is a major determinant of
bisphosphonates skeletal uptake (Lin, 1996). In the present study,
we have explored whether administration of ZA in the night, when
osteoclast activity is rising, could result in a greater suppression of
bone turnover as compared with suppression by the conventional
morning administration.
We did not find differential patterns of either bone resorption or
bone formation markers after ZA administration at opposite
phases of the circadian cycle. Yet analysis of the decremental
curves for serum CTX and urinary DPD yielded a significant trend
towards greater antiresorptive effect in the group of patients
receiving the drug at night. Even if this finding was not
substantiated by the significance in percent decreases from
baseline levels, it could be viewed in keeping with the concept
that ZA is more effective at the time of greater osteoclastic activity.
The administered dose is worth of attention. The widely used
4-mg/28-day schedule could be maximal at each time of the day. In
a setting of a lower loading, such as that indicated in patients with
impaired renal function, circadian susceptibility could better
emerge and be of clinical relevance. However, we did not measure
excretion of ZA in the very first days and perhaps, most
importantly, we did not assess the whole-body retention of the
drug (Cremers et al, 2005), which could have been informative in
this regard.
Anyway, the most interesting finding of our study could be
viewed in the differential response of PTH secretion as a function
of circadian phase. The mechanisms accounting for our data are
not obvious. Intravenous administration of potent bisphos-
phonates usually leads to hypocalcaemia and secondary hyper-
parathyroidism (which are mild and transient in many cases, but
may persist for a long time in others), with serum PTH level
increase depending on the status of vitamin D (Rosen and Brown,
2003; Breen and Shane, 2004; Caspar et al, 2004; Tanvetyanon and
Stiff, 2006). The two arms did not differ in 25-hydroxyvitamin D
levels. To the best of our knowledge, no data are available on the
possible direct effect of bisphosphonates on the steep sigmoidal
relationship between PTH levels and changes in the extracellular
concentration of calcium (Brown, 1983). Whatever the mechan-
isms, this finding could be of clinical relevance. In a large
population recruited in the registration trials of ZA, hyperpara-
thyroidism after ZA administration has been recently associated
with worse prognosis (Berruti et al, 2006). Moreover, in a
retrospective analysis, PTH levels before treatment with ZA were
higher in patients who subsequently developed osteonecrosis of
the jaw with respect to those who did not; patients developing this
severe complication also showed lower calcium and higher PTH
levels throughout treatment with ZA (Ardine et al, 2006). It is
unknown whether sustained excess PTH secretion in bone
metastatic patients reflects poor clinical conditions independently
of therapy, or whether it has a role in the disease progression due
to direct or indirect effects on tumour growth.
To conclude, the smaller increase in PTH level after ZA
administration in the night could be viewed as an additional piece
of evidence supporting differential effects of the drug as a function
of the administration hour. The clinical implications in terms
of anti-resorptive efficacy and PTH level changes deserve to be
further tested in specifically tailored protocols.
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